Cim LLC Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Cim LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 71,573 shares of the company’s stock, valued at approximately $1,445,000.

Several other large investors also recently bought and sold shares of HIMS. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC boosted its stake in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares during the last quarter. Van ECK Associates Corp purchased a new stake in Hims & Hers Health in the 2nd quarter valued at $111,000. Belpointe Asset Management LLC increased its stake in shares of Hims & Hers Health by 10.0% in the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after acquiring an additional 1,205 shares during the last quarter. Finally, Amalgamated Bank raised its holdings in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after acquiring an additional 2,354 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 4.9 %

Hims & Hers Health stock opened at $19.32 on Wednesday. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74. The firm has a market cap of $4.15 billion, a PE ratio of -1,931.50 and a beta of 1.05. The company’s 50 day moving average is $16.82 and its two-hundred day moving average is $17.25.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.03) EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $16.47, for a total value of $3,110,985.36. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $551,777.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the sale, the director now directly owns 23,917 shares in the company, valued at approximately $362,342.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $551,777.94. The disclosure for this sale can be found here. In the last three months, insiders sold 542,585 shares of company stock valued at $8,751,851. Insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of a number of analyst reports. TD Cowen upped their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Jefferies Financial Group lifted their target price on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 27th. Finally, Truist Financial upped their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.